Emeramed has discontinued our early access program in most of the world
to focus our efforts on bringing Irminix® to market as soon as possible.
Early Access is ONLY available in New Zealand and Lebanon,
before sending inquiries please read this information
Additionally, Irminix® has not been approved for pediatric use
The scientific literature has firmly established that mercury causes a biochemical train wreck especially in the brain where it is linked to a host of neurological illnesses and oxidative stress.
Learn about our company, mission and board of directors.
Irminix® has been approved for compassionate use.
Latest News, Research, Clinical Trials, Press and Newsletters.
Investor Information about EmeraMed Ltd.
Discover The Future of Health
We are committed to improving health by way of our unique metal chelator and antioxidant, Irminix®